CL2013000097A1 - Composicion farmaceutica combinada que incluye una forma activada potenciada de un anticuerpo de la proteina s-100 y una forma activada potenciada de un anticuerpo anti tnf-alfa; metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal. - Google Patents

Composicion farmaceutica combinada que incluye una forma activada potenciada de un anticuerpo de la proteina s-100 y una forma activada potenciada de un anticuerpo anti tnf-alfa; metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal.

Info

Publication number
CL2013000097A1
CL2013000097A1 CL2013000097A CL2013000097A CL2013000097A1 CL 2013000097 A1 CL2013000097 A1 CL 2013000097A1 CL 2013000097 A CL2013000097 A CL 2013000097A CL 2013000097 A CL2013000097 A CL 2013000097A CL 2013000097 A1 CL2013000097 A1 CL 2013000097A1
Authority
CL
Chile
Prior art keywords
activated form
antibody
enhanced activated
diseases
protein
Prior art date
Application number
CL2013000097A
Other languages
English (en)
Inventor
Oleg Lliich Epshtein
Original Assignee
Epshtein Oleg Iliich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44863147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2013000097(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from RU2010129293/15A external-priority patent/RU2500427C2/ru
Priority claimed from RU2011124809/15A external-priority patent/RU2532323C2/ru
Application filed by Epshtein Oleg Iliich filed Critical Epshtein Oleg Iliich
Publication of CL2013000097A1 publication Critical patent/CL2013000097A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0004—Homeopathy; Vitalisation; Resonance; Dynamisation, e.g. esoteric applications; Oxygenation of blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nutrition Science (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CL2013000097A 2010-07-15 2013-01-10 Composicion farmaceutica combinada que incluye una forma activada potenciada de un anticuerpo de la proteina s-100 y una forma activada potenciada de un anticuerpo anti tnf-alfa; metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal. CL2013000097A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010129293/15A RU2500427C2 (ru) 2010-07-15 2010-07-15 Лекарственное средство для лечения функциональных нарушений желудочно-кишечного тракта и способ лечения функциональных нарушений желудочно-кишечного тракта
RU2011124809/15A RU2532323C2 (ru) 2011-06-20 2011-06-20 Лекарственное средство для лечения патологического синдрома и способ лечения функциональных нарушений кишечника

Publications (1)

Publication Number Publication Date
CL2013000097A1 true CL2013000097A1 (es) 2015-01-09

Family

ID=44863147

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2013000097A CL2013000097A1 (es) 2010-07-15 2013-01-10 Composicion farmaceutica combinada que incluye una forma activada potenciada de un anticuerpo de la proteina s-100 y una forma activada potenciada de un anticuerpo anti tnf-alfa; metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal.

Country Status (23)

Country Link
US (1) US8637030B2 (es)
EP (1) EP2593138A2 (es)
JP (2) JP2013532181A (es)
KR (1) KR101901465B1 (es)
CN (1) CN103096927A (es)
AR (1) AR082245A1 (es)
AU (1) AU2011278032B2 (es)
BR (1) BR112013000842A2 (es)
CA (1) CA2804964C (es)
CL (1) CL2013000097A1 (es)
DE (1) DE112011102355T5 (es)
EA (1) EA030542B1 (es)
ES (1) ES2425004R1 (es)
FR (1) FR2962651A1 (es)
GB (1) GB2496794B (es)
IL (1) IL224215A (es)
IT (1) ITTO20110628A1 (es)
MX (1) MX2013000542A (es)
MY (1) MY157564A (es)
NZ (1) NZ606765A (es)
PE (1) PE20130397A1 (es)
SG (1) SG187035A1 (es)
WO (1) WO2012007839A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2181297C2 (ru) * 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
RU2309732C1 (ru) * 2006-03-13 2007-11-10 Олег Ильич Эпштейн Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
NZ606767A (en) 2010-07-15 2015-08-28 Oleg Iliich Epshtein A method of increasing the effect of an activated-potentiated form of an antibody
AU2011287288A1 (en) 2010-07-15 2013-03-07 Oleg Iliich Epshtein Combination pharmaceutical composition and methods of treating diseases or conditions associated with neurodegenerative diseases
CA2805091A1 (en) 2010-07-15 2012-01-19 Oleg Iliich Epshtein Pharmaceutical compositions comprising a homopathically potentized form of an antibody to human cannabinoid receptor
GB2495885B (en) * 2010-07-15 2017-11-22 Iliich Epshtein Oleg Combination pharmaceutical composition and methods of treating genitourinary system disorders
MX2013000807A (es) 2010-07-21 2013-10-28 Oleg Iliich Epshtein Un metodo para el tratamiento del trastorno de hiperactividad con deficit de atencion.
DE112011102412T5 (de) 2010-07-21 2013-07-04 Oleg Iliich Epshtein Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von mit Atemwegserkrankungen bzw. Atemwegsleiden assoziierten Erkrankungen bzw. Leiden
UY33679A (es) 2010-10-22 2012-03-30 Esbatech Anticuerpos estables y solubles
RU2013111962A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
RU2013111961A (ru) 2013-03-18 2014-09-27 Олег Ильич Эпштейн Способ определения выраженности модифицирующей активности, ассоциированной с носителем
CN106349388B (zh) * 2015-07-17 2021-04-02 上海佳文英莉生物技术有限公司 一种促细胞程序性坏死抗体及其应用
CN207908510U (zh) 2016-09-21 2018-09-25 维布兰特公司 安装在抽水马桶上的传感器
WO2024111633A1 (ja) * 2022-11-24 2024-05-30 国立大学法人徳島大学 タンパク質に対する抗体の作製

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4311897A (en) 1979-08-28 1982-01-19 Union Carbide Corporation Plasma arc torch and nozzle assembly
US4963367A (en) 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
US4987127A (en) 1989-01-31 1991-01-22 Dal Sirany Method of treating a virus outbreak
SU1730144A1 (ru) 1989-02-24 1992-04-30 Научный Центр По Разработке И Внедрению Современных Методов Молекулярной Диагностики Способ подавлени репродукции вирусов
GB8905400D0 (en) 1989-03-09 1989-04-19 Jonker Margreet Medicaments
US5698195A (en) 1991-03-18 1997-12-16 New York University Medical Center Methods of treating rheumatoid arthritis using chimeric anti-TNF antibodies
RU2007989C1 (ru) 1991-11-12 1994-02-28 Акционерное общество "Трейдис" Способ габович подбора гомеопатических препаратов и их разовой дозы
US5741488A (en) 1992-10-08 1998-04-21 The Kennedy Institute For Rheumatology Treatment of rheumatoid arthritis with anti-CD4 antibodies in conjunction with anti-TNF antibodies
DK140992D0 (da) 1992-11-24 1992-11-24 Ole Buchardt Fremgangsmaade til frembringelse af antistoffer mod haptener og andre b-celle-antigener, antistoffer opnaaet ved fremgangsmaaden og anvendelse af disse antistoffer til fremstilling af vacciner, isaer til veterinaermedicinsk brug
US5879677A (en) 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
RU2033784C1 (ru) 1993-05-28 1995-04-30 Индивидуальное частное предприятие "Диалог" Устройство для репродуцирования гомеопатических и изопатических препаратов
IT1261849B (it) 1993-09-02 1996-06-03 Avantgarde Spa Dispositivo medico per la somministrazione di principi attivi o farmaci a bassissimo dosaggio, in particolare di farmaci omeopatici.
EP0652014A1 (en) 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
NZ278607A (en) 1994-02-07 1999-05-28 Knoll Ag Use of tnf antagonists for treating disorders involving elevated serum levels of il-6 wherein the serum levels are 500pg/ml or above
DE69535592T2 (de) 1994-03-25 2008-06-12 Isotechnika, Inc., Edmonton Verbesserung der effektivität von arzneimitteln duren deuterierung
US5629286A (en) 1994-03-31 1997-05-13 Brewitt; Barbara Homeopathic dilutions of growth factors
IL110035A0 (en) 1994-06-16 1994-10-07 Tapuach Natural Technologies 1 Homeopathic formulations
RU2137483C1 (ru) 1995-08-02 1999-09-20 Божедомов Владимир Александрович Способ лечения урогенитальной хламидийной, уреаплазменной и микоплазменной инфекции
EA000885B1 (ru) 1996-02-12 2000-06-26 Олег Ильич ЭПШТЕЙН Лекарственное средство и способ медикаментозного воздействия на организм
WO1997039772A1 (fr) 1996-04-19 1997-10-30 Chugai Seiyaku Kabushiki Kaisha Remede contre l'arthrite rhumatoide contenant un anticorps anti-il-8 comme principe actif
IL118096A0 (en) 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
RU2114605C1 (ru) 1996-09-30 1998-07-10 Олег Ильич Эпштейн Защитная добавка для косметических средств
RU2132181C1 (ru) 1996-09-30 1999-06-27 Эпштейн Олег Ильич Средство для воздействия на организм
RU2114646C1 (ru) 1996-09-30 1998-07-10 Олег Ильич Эпштейн Способ повышения защитных свойств организма при воздействии внешних физических факторов
RU2099052C1 (ru) 1996-12-26 1997-12-20 Тамара Михайловна Воробьева Лекарственное средство для восстановления психофизиологического гомеостаза, нарушенного вследствие употребления алкоголя
RU2103999C1 (ru) 1997-01-31 1998-02-10 Олег Ильич Эпштейн Способ лечения алкоголизма
RU2104006C1 (ru) 1997-02-14 1998-02-10 Олег Ильич Эпштейн Способ лечения наркомании
RU2104032C1 (ru) 1997-03-11 1998-02-10 Общество с ограниченной ответственностью "Снежный барс" Способ усиления лечебного эффекта лекарственных средств
DE19746868A1 (de) 1997-10-23 1999-04-29 Knoll Ag Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
RU2122858C1 (ru) 1997-12-29 1998-12-10 Яковлева Людмила Борисовна Гомеопатическое лекарственное средство седативного действия "вернисон"
RU2187334C2 (ru) 1998-05-22 2002-08-20 Эпштейн Олег Ильич Способ коррекции нарушенного иммунного гомеостаза и лекарственное средство
RU2161955C1 (ru) 1999-07-16 2001-01-20 Эпштейн Олег Ильич Способ изменения физико-химических или физико-химических и биологических свойств вещества
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
RU2177795C1 (ru) 2001-02-15 2002-01-10 Эпштей Олег Ильич Гомеопатическое лекарственное средство для лечения и профилактики аденовирусных инфекций у детей
RU2192882C1 (ru) 2001-04-18 2002-11-20 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
RU2197266C1 (ru) * 2001-06-01 2003-01-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения эрозивных и воспалительных заболеваний желудочно-кишечного тракта
WO2003037372A1 (fr) 2001-10-31 2003-05-08 Oleg Iliich Epshtein Procede de retablissement de processus physiologiques perturbes et medicament
RU2201255C1 (ru) 2001-12-26 2003-03-27 Эпштейн Олег Ильич Лекарственное средство и способ регуляции сосудистого тонуса
RU2001134982A (ru) 2001-12-26 2004-02-20 Олег Ильич Эпштейн Способ коррекции иммунного ответа и лекарственное средство
RU2205026C1 (ru) 2002-03-15 2003-05-27 Эпштейн Олег Ильич Лекарственное средство и способ лечения патологического синдрома, обусловленного нарушением кроветворения
UA76641C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Гомеопатичний лікарський засіб та спосіб лікування захворювань передміхурової залози
UA76640C2 (uk) 2002-08-02 2006-08-15 Олєг Ільіч Епштєйн Спосіб корекції патологічних імунних реакцій та гомеопатичний лікарський засіб
UA76638C2 (en) 2002-08-02 2006-08-15 Oleh Illich Epshtein Homeopathic medication based on anti-interferon antibodies and method for treating a pathological syndrome associated with interferon
TWI345470B (en) 2003-03-14 2011-07-21 Nutrition Res Inc Homeopathic formulations useful for treating pain and/or inflammation

Also Published As

Publication number Publication date
CN103096927A (zh) 2013-05-08
MY157564A (en) 2016-06-30
NZ606765A (en) 2015-08-28
EP2593138A2 (en) 2013-05-22
GB2496794A (en) 2013-05-22
EA030542B1 (ru) 2018-08-31
US20130004574A1 (en) 2013-01-03
KR20130060264A (ko) 2013-06-07
EA201300125A1 (ru) 2013-12-30
KR101901465B1 (ko) 2018-09-21
ITTO20110628A1 (it) 2012-01-16
AU2011278032A1 (en) 2013-03-07
GB201302654D0 (en) 2013-04-03
ES2425004R1 (es) 2014-07-09
SG187035A1 (en) 2013-02-28
WO2012007839A3 (en) 2012-04-26
FR2962651A1 (fr) 2012-01-20
JP2016210787A (ja) 2016-12-15
AU2011278032B2 (en) 2015-07-23
MX2013000542A (es) 2013-06-28
ES2425004A2 (es) 2013-10-10
DE112011102355T5 (de) 2013-04-25
CA2804964C (en) 2016-06-28
AR082245A1 (es) 2012-11-21
IL224215A (en) 2016-03-31
WO2012007839A2 (en) 2012-01-19
CA2804964A1 (en) 2012-01-19
BR112013000842A2 (pt) 2016-06-07
PE20130397A1 (es) 2013-04-10
JP2013532181A (ja) 2013-08-15
US8637030B2 (en) 2014-01-28
GB2496794B (en) 2017-11-01

Similar Documents

Publication Publication Date Title
CL2013000097A1 (es) Composicion farmaceutica combinada que incluye una forma activada potenciada de un anticuerpo de la proteina s-100 y una forma activada potenciada de un anticuerpo anti tnf-alfa; metodos para el tratamiento de las enfermedades o condiciones funcionales del tracto gastrointestinal.
IL274646A (en) Integrated continuous production of medicinal substances from medical protein
CY2017019I1 (el) Παραγοντες που επηρεαζουν αποπτωση για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
CL2012001304A1 (es) Anticuerpo o fragmento de enlace a antígeno del mismo que se une al péptido humano c5a del sistema del complemento; composición farmacéutica que lo comprende; y su uso para el tratamiento de enfermedades inflamatorias agudas.
BR112015002524A2 (pt) derivados de alquilpirimidina para o tratamento de infecções virais e outras doenças.
BR112015023124A2 (pt) liberação de organismos probióticos e/ou agentes terapêuticos almejada para o trato gastrintestinal
CL2015001231A1 (es) Compuestos heterocíclicos sustituidos con amida; composicion farmaceutica; útiles en el tratamiento de una enfermedad inflamatoria o autoinmune.
CL2015000061A1 (es) Anticuerpos biespecíficos anti-vegf/anti-ang-2 y su utilización en el tratamiento de enfermedades vasculares oculares
IL239735B (en) A pharmaceutical preparation for the treatment of diseases related to toxic aldehyde
CL2013000201A1 (es) Composiciones farmaceuticas combinadas que comprenden una forma activada potenciada de anticuerpos contra la proteina s-100 de cerebro y una forma activada potenciada de anticuerpos contra nos endotelial; metodo de tratamiento del vertigo la cinetosis y la distonia vegetativa-vascular.
EP3010938A4 (en) Fcrn-specific human antibody and composition for treatment of autoimmune diseases
HK1222331A1 (zh) 修飾的繆勒抑制物質 蛋白及其用於疾病治療的用途
CL2013000202A1 (es) Composicion farmaceutica y combinacion compuesta por una forma potenciada activada de un anticuerpo contra la bradiquinina, una forma potenciada activada de una histamina y una forma potenciada activada de un anticuerpo contra la morfina; metodos para tratar las enfermedades o las condiciones asociadas con la enfermedad o condicion respiratoria.
ES2542042R1 (es) Composiciones farmacéuticas y uso para preparar un medicamento destinado al tratamiento de la obesidad, los trastornos metabólicos relacionados y la adicción a sustancias psicoactivas
WO2014151456A3 (en) Treatment of inflammatory diseases
BR112014009789A2 (pt) cisteamina no tratamento da doença fibrótica
MA39950A (fr) Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie
DE102009018133A8 (de) Pharmazeutische Zusammensetzung zur Behandlung von dermatologischen Autoimmunerkrankungen
EP3045180A4 (en) Combinations of aggregating proteins and molecular chaperone proteins for the treatment of proteinopathies or conformational diseases
EP2966087A4 (en) ANTIBODY TO A PEPTIDE CODED BY EXON-21 OF PERIOSTIN, AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF INFLAMMATORY DISEASE CONTAINING SAID ANTIBODY
BR112017021413A2 (pt) anticorpos anti-flt-1 no tratamento da displasia broncopulmonar.
CL2015001520A1 (es) Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares
BRPI0908602A2 (pt) método e composição farmacêutica para o tratamento de doenças autoimunes.
WO2015003049A3 (en) Compositions and methods to treat inflammatory joint disease
EA201301340A1 (ru) Фармацевтическая композиция, обладающая нейропротекторным действием, её применение и способы повышения жизнеспособности и профилактики или лечения цереброваскулярных и нейродегенеративных заболеваний